Infectious Disease Diagnostic Market by Product, Technology, Testing Type, Sample, Application, End User

Description

List of Tables

[183 Pages Report] The Infectious Disease Diagnostic Market size was estimated at USD 24.76 billion in 2023 and expected to reach USD 26.44 billion in 2024, at a CAGR 7.29% to reach USD 40.53 billion by 2030.

Infectious disease diagnostics products are designed to detect and identify pathogens that cause human infections. These diagnostics play a critical role in healthcare by facilitating the accurate and timely recognition of infectious agents, thus ensuring prompt and appropriate clinical management. The modalities for infectious disease diagnostics include culture techniques, molecular diagnostics, serology, antigen-based tests, and next-generation sequencing for guiding treatment decisions, monitoring disease outbreaks, and implementing infection control measures to prevent the spread of pathogens within communities and healthcare settings. In recent years, outbreaks of infectious diseases have resulted in an urgent need for reliable diagnostics. In addition, growth in healthcare spending and improvements in laboratory infrastructure globally contribute to the penetration of infectious disease diagnostic solutions. Moreover, government initiatives and regulatory approvals for innovative diagnostic solutions have expanded the availability of novel infectious disease diagnostic solutions. However, high costs associated with advanced diagnostic technologies could limit adoption in cost-sensitive regions. The lack of skilled professionals in emerging markets to operate sophisticated diagnostic equipment may restrict product penetration. Nevertheless, the integration of advanced technologies for enhanced data analysis and interpretation of complex diagnostic tests has enhanced the outputs of diagnostic tests. In addition, continuous development in diagnostic technologies, including rapid PCR systems and next-generation sequencing, drives the demand for infectious disease diagnostics products by offering quicker and more accurate results.

KEY MARKET STATISTICS
Base Year [2023]	USD 24.76 billion
Estimated Year [2024]	USD 26.44 billion
Forecast Year [2030]	USD 40.53 billion
CAGR (%)	7.29%

Product: Advancing applications of analytical instruments for infectious disease diagnostics

The instruments include various analytical devices for diagnosing infectious diseases, ranging from essential laboratory equipment to sophisticated diagnostic machines such as PCR systems, immunoassays, microbiology cultures, and molecular diagnostics platforms. Instruments are crucial for laboratories, hospitals, and clinics requiring in-house testing for fast and reliable results. Reagents constitute the biochemical substances and mixtures used to detect pathogens in clinical samples. Reagents include primers, probes, enzymes, and buffers for PCR tests, antibodies for immunoassays, and various culture media for bacterial growth. Different diseases require specific reagents for accurate detection; hence, the preference varies based on the pathogen of interest. Software & services include data analysis software, interoperability solutions for integrating various diagnostic platforms, and services such as lab management, technical support, and consultancy. Software and services are critical for practically interpreting diagnostic tests and integrating diagnostics data with patient records. Providers usually prefer software that offers ease of use, robust data analysis capabilities, and compatibility with existing systems.

Testing Type: Emerging adoption of Point-of-Care (PoC) testing for convenience and emergency applications

Laboratory testing analyzes samples to detect infectious diseases, which is done in a controlled environment with specialized equipment. Laboratory testing is often considered the gold standard due to its high accuracy and ability to provide comprehensive results. The preference for laboratory testing arises from the need for precise and detailed diagnostics that can guide effective treatment plans. With its enhanced precision and capacity for comprehensive analysis, laboratory testing is the more reliable option for definitive diagnostics and is suited for complex cases with less time sensitivity. On the other hand, Point-of-Care (PoC) testing is diagnostic testing performed at or near the site of patient care. The critical advantage of PoC testing is its convenience and the rapidity with which results can be obtained, which is essential in clinical decision-making. PoC testing can be performed with portable instruments or simple test kits, such as lateral flow assays, and is necessary in resource-limited settings or situations where immediate results are required.

Application: Increasing use of disease diagnosis kits to diagnose viral infections

Diagnostics for bacterial infections involve the identification of pathogenic bacteria that can cause disorders such as tuberculosis, pneumonia, and urinary tract infections. Need-based preference for bacterial diagnostics is high in healthcare settings where rapid diagnostic tools are essential for timely treatment, thus reducing the spread of infections. Diagnostics for cardiovascular infections involve molecular tests and serology testing to detect pathogenic organisms. Central Nervous System (CNS) infections can include meningitis and encephalitis and require rapid and accurate diagnostics due to their potential severity. Fungal infection diagnostics are essential for immunocompromised patients, where infections including candidiasis and aspergillosis can be life-threatening. Diagnostic tests range from traditional culture methods to advanced molecular diagnostic platforms to diagnose fungal disorders. Diagnostics for sexually transmitted diseases (STDs) such as HIV, HPV, chlamydia, and gonorrhea are crucial for public health. These diagnostics have a high need-based preference because they affect a large demographic and can have serious reproductive health consequences. Viral diagnostics cover various diseases, including influenza, hepatitis, and emerging pathogens.

End-User: Penetration of infectious disease diagnosis products in hospitals

Diagnostic laboratories are specialized facilities where infectious disease tests are conducted. They require high throughput systems, scalability, and comprehensive test menus to cater to varied diagnostic needs. Diagnostic laboratories prioritize automated platforms, integration with laboratory information systems, and cost-effective testing to handle high volumes of samples. Hospitals form a critical point of care for patients suffering from infectious diseases. Hospitals require diagnostic tools that are fast, accurate, and can be easily integrated into the patient care workflow within their facilities. Hospitals seek diagnostic solutions that minimize time to diagnosis to improve patient management and isolation protocols, such as point-of-care testing devices. Research institutes focus on studying infectious diseases to understand their nature and develop new diagnostic technologies. Research institutes require sophisticated and susceptible equipment to detect and study pathogens at a molecular level. Research institutes are interested in cutting-edge technology, versatility in testing capabilities, and access to various assays for different pathogens.

Regional Insights

The infectious disease diagnostic market in the Americas is observing rapid growth due to the increasing prevalence of infectious diseases, advanced diagnostic technologies, and growing awareness of early disease detection. The adoption of advanced technologies, well-established healthcare infrastructure, and the presence of the majority of vendors contribute to the infectious disease diagnostic market in the Americas. European Union's (EU) regulations and a sophisticated healthcare system largely influence Europe's market. EU countries invest heavily in research and innovation, exemplified by initiatives to foster the development of advanced diagnostics and resonate with proactive customer behavior toward disease prevention and management. The Middle East market is directed by significant healthcare spending and the adoption of high-tech diagnostic equipment, particularly in Gulf Cooperation Council (GCC) countries. The need for accessible and affordable diagnostics to combat prevalent infectious diseases such as HIV/AIDS, tuberculosis, and malaria has improved the need for infectious disease diagnosis products in Africa. The infectious disease diagnostic market in the Asia-Pacific is expanding rapidly due to its large population and increased healthcare expenditure. The government's focus on healthcare reform and the rise of domestic companies contribute to the growth of infectious disease diagnostics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Infectious Disease Diagnostic Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Infectious Disease Diagnostic Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Infectious Disease Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Techne Corporation, bioMerieux SA, Cardinal Health Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Grifols, S.A., Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Labsystems Diagnostics Oy, Merck KGaA, Olympus Corporation, Perkin Elmer, Inc., Pfizer Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Infectious Disease Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Instruments
- Reagents
- Software & Services

Technology
- Biochemical Technology
- Conventional Technology
- Molecular Technology

Testing Type
- Laboratory Testing
- PoC Testing

Sample
- Blood, Plasma, & Serum
- Urine

Application
- Bacterial Infection
- Cardiovascular Infection
- CNS Infection
- Fungal Infection
- Sexually Transmitted Disease
- Viral Infection

End User
- Diagnostic Laboratories
- Hospital
- Research Institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Infectious Disease Diagnostic Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Infectious Disease Diagnostic Market?

3. What are the technology trends and regulatory frameworks in the Infectious Disease Diagnostic Market?

4. What is the market share of the leading vendors in the Infectious Disease Diagnostic Market?

5. Which modes and strategic moves are suitable for entering the Infectious Disease Diagnostic Market?

Product Code: MRR-4316E4E89510

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing global prevalence and periodic outbreaks of infectious diseases
  - 5.1.1.2. Shift in focus towards decentralized point-of-care testing from centralized laboratories
  - 5.1.1.3. Supportive government initiatives and investments toward infectious disease control and prevention
- 5.1.2. Restraints
  - 5.1.2.1. Inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in infectious disease diagnostics kits and solutions
  - 5.1.3.2. Emergence of infectious disease diagnostics kits for homecare settings
- 5.1.4. Challenges
  - 5.1.4.1. Accuracy issues and limited availability of skilled professionals
5.2. Market Segmentation Analysis
- 5.2.1. Product: Advancing applications of analytical instruments for infectious disease diagnostics
- 5.2.2. Testing Type: Emerging adoption of Point-of-Care (PoC) testing for convenience and emergency applications
- 5.2.3. Application: Increasing use of disease diagnosis kits to diagnose viral infections
- 5.2.4. End-User: Penetration of infectious disease diagnosis products in hospitals
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Infectious Disease Diagnostic Market, by Product

6.1. Introduction
6.2. Instruments
6.3. Reagents
6.4. Software & Services

7. Infectious Disease Diagnostic Market, by Technology

7.1. Introduction
7.2. Biochemical Technology
7.3. Conventional Technology
7.4. Molecular Technology

8. Infectious Disease Diagnostic Market, by Testing Type

8.1. Introduction
8.2. Laboratory Testing
8.3. PoC Testing

9. Infectious Disease Diagnostic Market, by Sample

9.1. Introduction
9.2. Blood, Plasma, & Serum
9.3. Urine

10. Infectious Disease Diagnostic Market, by Application

10.1. Introduction
10.2. Bacterial Infection
10.3. Cardiovascular Infection
10.4. CNS Infection
10.5. Fungal Infection
10.6. Sexually Transmitted Disease
10.7. Viral Infection

11. Infectious Disease Diagnostic Market, by End User

11.1. Introduction
11.2. Diagnostic Laboratories
11.3. Hospital
11.4. Research Institutes

12. Americas Infectious Disease Diagnostic Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Infectious Disease Diagnostic Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Infectious Disease Diagnostic Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
- 15.3.1. Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering
- 15.3.2. Oxford Nanopore and bioMerieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
- 15.3.3. Thermo Fisher Scientific Launches PCR Kits for Infectious Disease Detection in India
15.4. Strategy Analysis & Recommendation

16. Competitive Portfolio

16.1. Key Company Profiles
16.2. Key Product Portfolio